Research
in two major platforms
Antiviral Platform
NMDA Platform
Pipeline
A rapidly expanding pipeline of late-phase clinical trials
COVID-19
— This is a Phase 2 trial testing the safety and efficacy of Pentarlandir for early and mildly symptomed COVID-19 patients. The trial was completed in June 2022. A Phase 3 trial is expected to launch in H2 2022.
— The antiviral efficacy for Pentarlandir covers different variants of COVID-19 since Pentarlandir targets two essential conservative enzymes during virus replication.
— To learn more about the trial and to participate, click here.
Airnecflu
COVID-19
Schizophrenia
— This is a Phase 2/3 trial testing the safety and efficacy of ClozaBen for adults schizophrenia who are not responding to at least 2 existing antipsychotics. The trial is currently ongoing in the US, EU, and Taiwan.
— ClozaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid.
— To learn more about the trial and to participate, click here.
SND4
Adult Schizophrenia
— This is a novel and potent compound in preclinical phase as a promising candidate for add-on therapy of adult schizophrenia.
— SND4 is a small-molecule compound with exceptional potency against D-amino acid oxidase and has been demonstrated significant in vivo efficacy for treating NMDA hypofunction-induced CNS disorders.
Dementia
NaBen
Early Dementia
— This is a Phase 2/3-ready trial, approved by the US FDA, to test the safety and efficacy of NaBen to stop or even to reverse the course of disease progression. The IND was approved by the US FDA.
— The function of NMDA receptor is highly associated with the cognitive impairments caused by Alzheimer’s Disease. NaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid.
— To learn more about the trial and to participate, click here.
Tannquilynne
Dementia with Psychosis
— This is a Phase 2-ready trial, approved by the US FDA, to test the safety and efficacy of Tannquilynne to treat mild-to-moderate Alzheimer’s cognitive impairment and its associated psychosis symptoms.
— Tannquilynne is a potent DAAO inhibitor with a well-known safety profile and human use history. Inhibition of DAAO is contributes to the enhancement of NMDAR-mediated neurotransmission via reducing the metabolism of D amino acid.
— To learn more about the trial and to participate, click here.
Depression
Synapsinae
Depression and suicidality
— This is a Phase 3-ready trial, approved by the US FDA, to test the safety and efficacy of Synapsinae to treat depression and suicidality for the major depressive disorder (MDD) population.
— Synapsinae is a potent Glycine Transporter 1 (GlyT-1) inhibitor. Inhibition of GlyT-1 can block glycine uptake and enhance the function of NMDA receptor.
— To learn more about the trial and to participate, click here.
Synxyrin
Refractory depression
— This is a Phase 2-ready trial, approved by the US FDA, to test the safety and efficacy of Synxyrin to treat the patients of major depression disorder (MDD) who did not respond to at least two existing antidepressants.
— Synxyrin is a potent mixed agonist / antagonist for the NMDA receptor. As a partial agonist of NMDAR, Synxyrin balances the NMDA-receptor-mediated neurotransmission.
— To learn more about the trial and to participate, click here.
— This is a Phase 2 trial testing the safety and efficacy of Pentarlandir for early and mildly symptomed COVID-19 patients. The trial was completed in June 2022. A Phase 3 trial is expected to launch in H2 2022.
— The antiviral efficacy for Pentarlandir covers different variants of COVID-19 since Pentarlandir targets two essential conservative enzymes during virus replication.
— To learn more about the trial and to participate, click here.
— This is a Phase 2/3 trial testing the safety and efficacy of NaBen as a add-on therapy for adult schizophrenia. The trial is currently ongoing in the US, EU, and Taiwan.
— NaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid.
— To learn more about the trial and to participate, click here.
— This is a Phase 2/3 trial testing the safety and efficacy of ClozaBen for adults schizophrenia who are not responding to at least 2 existing antipsychotics. The trial is currently ongoing in the US, EU, and Taiwan.
— ClozaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid.
— To learn more about the trial and to participate, click here.
— This is a Phase 2/3 trial testing the safety and efficacy of NaBen as a add-on therapy for adolescent schizophrenia. The trial is currently ongoing in the US, EU, and Taiwan.
— NaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid.
— To learn more about the trial and to participate, click here.
— This is a Phase 2/3-ready trial, approved by the US FDA, to test the safety and efficacy of NaBen to stop or even to reverse the course of disease progression. The IND was approved by the US FDA.
— The function of NMDA receptor is highly associated with the cognitive impairments caused by Alzheimer’s Disease. NaBen is a DAAO inhibitor with a well-established safety profile and has been proved to enhance the function of NMDA receptors through reducing the metabolism of D-amino acid.
— To learn more about the trial and to participate, click here.
— This is a Phase 2-ready trial, approved by the US FDA, to test the safety and efficacy of Tannquilynne to treat mild-to-moderate Alzheimer’s cognitive impairment and its associated psychosis symptoms.
— Tannquilynne is a potent DAAO inhibitor with a well-known safety profile and human use history. Inhibition of DAAO is contributes to the enhancement of NMDAR-mediated neurotransmission via reducing the metabolism of D amino acid.
— To learn more about the trial and to participate, click here.
— This is a Phase 3-ready trial, approved by the US FDA, to test the safety and efficacy of Synapsinae to treat depression and suicidality for the major depressive disorder (MDD) population.
— Synapsinae is a potent Glycine Transporter 1 (GlyT-1) inhibitor. Inhibition of GlyT-1 can block glycine uptake and enhance the function of NMDA receptor.
— To learn more about the trial and to participate, click here.
— This is a Phase 2-ready trial, approved by the US FDA, to test the safety and efficacy of Synxyrin to treat the patients of major depression disorder (MDD) who did not respond to at least two existing antidepressants.
— Synxyrin is a potent mixed agonist / antagonist for the NMDA receptor. As a partial agonist of NMDAR, Synxyrin balances the NMDA-receptor-mediated neurotransmission.
— To learn more about the trial and to participate, click here.